Ann: Interim data in Phase 2 study of SNT-5505 in myelofibrosis, page-43

Little mention this morning ,,, wow peaked at $4 a share in 2007??? went from $800m MC to $110m.....
I would have thought Management would want to really apply the Market Messaging to bring market wide awareness to the SNT 5505 Phase II Top Line Data...

In 2001 Pharmaxis now Syntara (ASX:SNT) licensed patents for respiratory products from the Central Sydney Area Health Service (which included RPAH).

Pharmaxis funded later stage clinical trials necessary to get Aridol and Bronchitol, which are now available world-wide, approved. Its shares peaked in 2007 at over $4 a share – for a roughly $800 million market cap – mainly on its Bronchitol hopes.

The company announced sale of its mannitol respiratory unit, which included Aridol and Bronchitol, in October 2023 along with its rebrand to Syntara and change of focus to haematological malignancies.